Related Experiment Video
Updated: May 15, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
Yan-Fang Tao1, Jun Lu, Xiao-Juan Du
1Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China.
Background:
Survivin, a member of the family of inhibitor of apoptosis proteins, functions as a key regulator of mitosis and programmed cell death. YM155, a novel molecular targeted agent, suppresses survivin, which is overexpressed in many tumor types. The aim of this study was to determine the antitumor activity of YM155 in SK-NEP-1 cells.
Methods:
SK-NEP-1 cell growth in vitro and in vivo was assessed by MTT and nude mice experiments. Annexin V/propidium iodide staining followed by flow cytometric analysis was used to detect apoptosis in cell culture. Then gene expression profile of tumor cells treated with YM155 was analyzed with real-time PCR arrays. We then analyzed the expression data with MEV (Multi Experiment View) cluster software. Datasets representing genes with altered expression profile derived from cluster analyses were imported into the Ingenuity Pathway Analysis tool.
Results:
YM155 treatment resulted in inhibition of cell proliferation of SK-NEP-1cells in a dose-dependent manner. Annexin V assay, cell cycle, and activation of caspase-3 demonstrates that YM155 induced apoptosis in SK-NEP-1 cells. YM155 significantly inhibited growth of SK-NEP-1 xenografts (YM155 5 mg/kg: 1.45 ± 0.77 cm3; YM155 10 mg/kg: 0.95 ± 0.55 cm3) compared to DMSO group (DMSO: 3.70 ± 2.4 cm3) or PBS group cells (PBS: 3.78 ± 2.20 cm3, ANOVA P < 0.01). YM155 treatment decreased weight of tumors (YM155 5 mg/kg: 1.05 ± 0.24 g; YM155 10 mg/kg: 0.72 ± 0.17 g) compared to DMSO group (DMSO: 2.06 ± 0.38 g) or PBS group cells (PBS: 2.36 ± 0.43 g, ANOVA P < 0.01). Real-time PCR array analysis showed between Test group and control group there are 32 genes significantly up-regulated and 54 genes were significantly down-regulated after YM155 treatment. Ingenuity pathway analysis (IPA) showed cell death was the highest rated network with 65 focus molecules and the significance score of 44. The IPA analysis also groups the differentially expressed genes into biological mechanisms that are related to cell death, cellular function maintenance, cell morphology, carbohydrate metabolism and cellular growth and proliferation. Death receptor signaling (3.87E-19), TNFR1 signaling, induction of apoptosis by HIV1, apoptosis signaling and molecular mechanisms of cancer came out to be the top four most significant pathways. IPA analysis also showed top molecules up-regulated were BBC3, BIRC3, BIRC8, BNIP1, CASP7, CASP9, CD5, CDKN1A, CEBPG and COL4A3, top molecules down-regulated were ZNF443, UTP11L, TP73, TNFSF10, TNFRSF1B, TNFRSF25, TIAF1, STK17A, SST and SPP1, upstream regulator were NR3C1, TP53, dexamethasone , TNF and Akt.
Conclusions:
The present study demonstrates that YM155 treatment resulted in apoptosis and inhibition of cell proliferation of SK-NEP-1cells. YM155 had significant role and little side effect in the treatment of SK-NEP-1 xenograft tumors. Real-time PCR array analysis firstly showed expression profile of genes dyes-regulated after YM155 treatment. IPA analysis also represents new molecule mechanism of YM155 treatment, such as NR3C1 and dexamethasone may be new target of YM155. And our results may provide new clues of molecular mechanism of apoptosis induced by YM155.
Insights
YM155 effectively inhibits SK-NEP-1 cell proliferation and induces apoptosis, showing significant antitumor activity in xenograft models. This study reveals YM155
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Survivin is a key regulator of mitosis and apoptosis, often overexpressed in tumors.
- YM155 is a novel targeted agent designed to suppress survivin.
- SK-NEP-1 cells serve as a model for evaluating YM155's antitumor potential.
Purpose of the Study:
- To assess the antitumor activity of YM155 against SK-NEP-1 cells.
- To investigate the molecular mechanisms underlying YM155's effects.
- To explore potential new therapeutic targets for YM155 treatment.
Main Methods:
- In vitro and in vivo cell proliferation assays (MTT, nude mice xenografts).
- Apoptosis detection via Annexin V/propidium iodide staining and flow cytometry.
- Gene expression profiling using real-time PCR arrays and Ingenuity Pathway Analysis (IPA).
Main Results:
- YM155 dose-dependently inhibited SK-NEP-1 cell proliferation and induced apoptosis.
- Significant reduction in SK-NEP-1 xenograft tumor volume and weight was observed.
- Gene expression analysis revealed significant upregulation and downregulation of key genes involved in cell death pathways, with IPA highlighting cell death and cancer mechanisms.
Conclusions:
- YM155 demonstrates significant apoptosis-inducing and proliferation-inhibiting effects on SK-NEP-1 cells.
- YM155 shows efficacy in reducing xenograft tumor growth with minimal side effects.
- IPA analysis suggests potential new targets like NR3C1 and dexamethasone for YM155 therapy, offering insights into its molecular mechanism.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway

